Windmill Hill Asset Management Ltd Purchases 45,855 Shares of Centessa Pharmaceuticals PLC Sponsored ADR $CNTA

Windmill Hill Asset Management Ltd raised its position in shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 38.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 163,768 shares of the company’s stock after acquiring an additional 45,855 shares during the period. Centessa Pharmaceuticals makes up 0.6% of Windmill Hill Asset Management Ltd’s portfolio, making the stock its 12th biggest holding. Windmill Hill Asset Management Ltd’s holdings in Centessa Pharmaceuticals were worth $2,152,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in the business. HighMark Wealth Management LLC lifted its position in shares of Centessa Pharmaceuticals by 0.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 237,285 shares of the company’s stock worth $3,118,000 after purchasing an additional 1,500 shares during the last quarter. Trexquant Investment LP lifted its holdings in shares of Centessa Pharmaceuticals by 1.1% during the first quarter. Trexquant Investment LP now owns 263,994 shares of the company’s stock worth $3,796,000 after buying an additional 2,810 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its position in shares of Centessa Pharmaceuticals by 15,209.5% in the first quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock valued at $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter worth $47,000. Finally, Exome Asset Management LLC increased its position in Centessa Pharmaceuticals by 3.7% during the first quarter. Exome Asset Management LLC now owns 142,744 shares of the company’s stock worth $2,053,000 after acquiring an additional 5,028 shares during the period. 82.01% of the stock is currently owned by institutional investors.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $15.56, for a total transaction of $155,600.00. Following the transaction, the insider owned 122,279 shares of the company’s stock, valued at $1,902,661.24. This represents a 7.56% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mario Alberto Accardi sold 8,322 shares of the firm’s stock in a transaction dated Tuesday, July 29th. The shares were sold at an average price of $15.23, for a total value of $126,744.06. Following the completion of the transaction, the insider owned 208,163 shares in the company, valued at approximately $3,170,322.49. This represents a 3.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 205,286 shares of company stock worth $3,993,345 over the last ninety days. 7.09% of the stock is currently owned by insiders.

Centessa Pharmaceuticals Trading Up 0.7%

CNTA stock opened at $22.47 on Tuesday. The business has a fifty day moving average price of $19.90 and a 200 day moving average price of $15.62. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. The stock has a market capitalization of $3.01 billion, a price-to-earnings ratio of -12.55 and a beta of 1.57. Centessa Pharmaceuticals PLC Sponsored ADR has a fifty-two week low of $9.60 and a fifty-two week high of $24.57.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). Analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on CNTA shares. Lifesci Capital raised shares of Centessa Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, September 3rd. Wells Fargo & Company assumed coverage on Centessa Pharmaceuticals in a research report on Wednesday, September 3rd. They issued an “overweight” rating and a $31.00 price objective for the company. Truist Financial began coverage on Centessa Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $30.00 price objective on the stock. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a research note on Friday, August 29th. They issued an “outperform” rating and a $40.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, Centessa Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $32.38.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.